Drugs / ABEPRAZAN
ABEPRAZAN
Trials 31 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT06437951 | Jul 2024 → Jan 2025 | gastroesophageal reflux disease | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05868967 | Feb → May 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05812404 | Oct 2022 → Mar 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05574374 | Sep 2022 → Mar 2023 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT05304845 | Mar → May 2022 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT06508645 | Jan → Mar 2022 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT04827472 | Jan → Jun 2021 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04328766 | Sep → Nov 2020 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT04490434 | Jun → Aug 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04185805 | Dec 2019 → Feb 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04167267 | Nov → Dec 2019 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04003441 | Jun → Aug 2019 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT03574415 | Nov 2018 → Jan 2019 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03487562 | Apr 2018 → Jan 2019 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT02757144 | Mar 2016 → Feb 2017 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03184324 | Aug 2017 → Apr 2018 | gastroesophageal reflux disease | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07326904 | Sep → Oct 2024 | gastroesophageal reflux disease | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT06751121 | Feb 2024 → Apr 2025 | Helicobacter pylori infectious disease | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT06121830 | Aug 2023 → Jan 2025 | gastroesophageal reflux disease | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT05813561 | Dec 2021 → Jul 2022 | peptic esophagitis | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04784910 | May 2021 → Nov 2023 | peptic ulcer disease | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04341428 | Jul 2020 → Aug 2021 | esophagitis | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT04341454 | Jun 2020 → Aug 2021 | chronic gastritis | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT03811080 | Feb 2019 → Feb 2020 | gastroesophageal reflux disease | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT03736369 | Dec 2018 → Aug 2019 | esophagitis | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07533266 | Apr 2026 → Dec 2027 expected | — | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05946135 | Nov 2023 → Sep 2025 | — | Yonsei University | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07497893 | Dec 2026 → Nov 2029 expected | atrial fibrillation | Ewha Womans University Mokdong Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07479056 | Oct 2024 → Apr 2028 expected | acute coronary syndrome, coronary artery disorder | SUK MIN SEO | Recruiting | No outcome recorded |
| — | NCT04888819 | Feb → Jul 2021 | esophagitis | Konkuk University Medical Center | Unknown | No outcome recorded |
| — | NCT04613895 | Nov 2020 → May 2021 | esophagitis | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05149274 Comparator | Oct 2021 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABEPRAZAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594445 ↗ |
| Known as | DWP14012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03811080 ↗23 |
| Known as | Fexuprazan | “Fexuprazan, a novel potassium-competitive acid blocker, is expected to be used for the prevention of nonsteroidal anti-inflammatory drugs (NSAIDs) induced ulcer.” PMID 38700290 ↗ May 20247“Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis.” PMID 36789577 ↗ Feb 2023 |
| Known as | Fexuprazan Hydrochloride | “Drug: Fexuprazan Hydrochloride” NCT05946135 ↗ |
| Action | Inhibit | “Fexuprazan, a novel P-CAB, inhibits gastric acid secretion through reversible and potassium-competitive inhibition of the H⁺/K⁺-ATPase” NCT07326904 ↗ |
| Modality | Other / unclassified | “Fexuprazan group(P-CAB)” NCT07479056 ↗ |
| Modality | Small molecule | — CHEMBL4594445 ↗ |
| Route | Oral | “DWP14012 Amg, tablets, orally, single dose administration” NCT02757144 ↗ |